Hao Liu
Senior Director, Drug Discovery & Cancer Biology Solve Therapeutics
Hao Liu is a Senior Director, Drug Discovery & Cancer Biology at Solve Therapeutics, where he brings nearly two decades of research experience to the development of next-generation ADCs. A PhD trained immunologist, Hao has deep expertise in tumor immunology, translational research, and advanced cell-based and flow cytometry techniques. At Solve, he contributes to advancing differentiated ADC technologies designed to improve selectivity, stability, and therapeutic index. His background spans academic and industry-based translational science, supporting Solve’s mission to deliver more precise and effective cancer therapies.
Seminars
Wednesday 14th October 2026
Preclinical Evaluation of SLV-013: A Novel GPC1- Targeting ADC for the Treatment of Solid Tumors
- Providing the strategic rationale for targeting GPC-1, overall biology and comprehensive expression profiling across multiple cancer lineages and primary normal cells and tissues
- Developing GPC-1 targeting ADCs, utilizing a proprietary hydrophilic and highly stable linker technology
- Unveiling the preclinical characterization of SLV-013, including the cell binding, internalization, and in vitro and in vivo efficacy data
